Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update
Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager
Covered in this story
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.